Screener
ADMA Biologics ADMA ADMA Bio Manufacturing — Nonoperating Income Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
| Other income (expense), net | (20) | 150 | 130 |
| Income (loss) before taxes | 64,010 | (707) | 63,303 |
| Expenditures for additions to long-lived assets | 2,256 | - | 2,256 |
| Total assets | 453,538 | 21,864 | 475,402 |
| Reconciliation of revenues: |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's ADMA bio manufacturing — nonoperating income expense?
- ADMA Biologics (ADMA) reported ADMA bio manufacturing — nonoperating income expense of -$20K in Q2 2026.
- How has ADMA Biologics's ADMA bio manufacturing — nonoperating income expense changed year-over-year?
- ADMA Biologics's ADMA bio manufacturing — nonoperating income expense increased by 81.5% year-over-year, from -$108K to -$20K.
- What does ADMA bio manufacturing — nonoperating income expense mean?
- Captures financial results from activities outside the segment's primary manufacturing operations, such as interest income, interest expense, or foreign exchange gains and losses. It helps isolate the impact of financing and peripheral activities from core business performance.
Ask your AI about ADMA Biologics's adma bio manufacturing — nonoperating income expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude